Two new appointments to BioAlliance Pharma’s Supervisory Board in phase with the company’s development

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced the appointment of two new Board members.
The Supervisory Board has co-opted André Ulmann MD, PhD (founder and CEO of HRA Pharma since 1996) and the company ING Belgium (represented by Denis Biju-Duval, BEng, MBA, Head of ING Belgium’s private equity team since 2001) following the departure of Georges Hibon and Philippe Taranto.
“I wish to thank Georges Hibon and Philippe Taranto for their work, which greatly benefited from their international experience in pharmaceuticals and finance” stated Dominique Costantini, President and CEO, BioAlliance Pharma.
New Board member André Ulmann will contribute his entrepreneurial experience within HRA, a fast-growing European company which develops and commercializes drugs in the reproductive health and endocrinology markets. Furthermore, the core BioAlliance Pharma shareholder ING Belgium has confirmed its midterm commitment to the company.
“I am delighted to welcome these two major players with a reinforced presence of major shareholders in the Supervisory Board”, stated Jean-Marie Zacharie, Chairman of the Supervisory Board. “With their support BioAlliance Pharma will continue to strengthen its growth strategy”, added Dominique Costantini.
Furthermore, AGF Private Equity (another core shareholder and a current Board member) has appointed Rémi Droller (Partner, managing investments in Healthcare) as its permanent representative. Rémi Droller holds an M.Phil. in Molecular Biology and a Masters in Innovation Management.